News Results

There are 688,586 News Results

Jun 25, 2018
Millennium BlockChain to Take 10% Position in Synergy Quantum, At a 50 Million Dollar Valuation
LAS VEGAS and GENEVA, June 25, 2018 /PRNewswire/ -- Millennium BlockChain Inc. (OTC: MBLC) ("Millennium BlockChain" or the "Company"), a company focused on blockchain technologies and crypto-assets, today announced that...
Jun 25, 2018
New Late-Breaking Data at ADA Underscore Significant Benefits of Abbott's FreeStyle Libre System for People Living with Diabetes
ORLANDO, Fla., June 25, 2018 /PRNewswire/ -- Abbott today announced results from multiple new clinical and real-world studies that provide a comprehensive look at the global use of the FreeStyle...
Jun 25, 2018
AARP Invests $60M in the Dementia Discovery Fund to Kick-Start its 'Disrupt Dementia' Campaign
WASHINGTON, June 25, 2018 /PRNewswire-USNewswire/ -- With nearly 10 million new cases of dementia and Alzheimer's disease occurring each year(1), and no cure, today AARP launched a new campaign, "Disrupt...
Jun 25, 2018
Global Peptic Ulcer Testing Industry
NEW YORK, June 25, 2018 /PRNewswire/ --
Jun 25, 2018
Global Cystic Fibrosis Industry
NEW YORK, June 25, 2018 /PRNewswire/ --
Jun 25, 2018
Metformin Alone or Combined with Insulin Does Not Improve or Preserve Beta-Cell Function in Youth with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes
ORLANDO, Fla., June 25, 2018 /PRNewswire-USNewswire/ --
Jun 26, 2018
Only 33 Percent of Millennial Automotive Engineers Say Their Experience at Work Matches Their Organization's Portrayal of Itself
DETROIT, June 26, 2018 /PRNewswire/ --
Jul 5, 2018
BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease
STOCKHOLM, July 6, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced positive topline results from the Phase 2b study with BAN2401, an anti-amyloid beta protofibril antibody,...
Jul 9, 2018
Health Canada Approves GAZYVA® for Previously Untreated Advanced Follicular Lymphoma
GAZYVA is the first anti-CD20 treatment in 15 years for the most common subtype of indolent lymphoma.(1)
Jul 3, 2018
For The Second Year In A Row, Gastroenterologists Nationwide Endorse Non-Prescription FDgard® For Functional Dyspepsia (Meal-Triggered Indigestion) [i]
BOCA RATON, Fla., July 3, 2018 /PRNewswire/ -- IM HealthScience(®), innovators of medical foods and dietary supplements, today announced a high-quality, nationwide survey conducted among a representative and projectible sample...
68859

Pages

1

Stories of the day

Oct 9, 2025
Viasat Awarded Contract by U.S. Space Force for Protected Tactical SATCOM-...
Oct 9, 2025
Damen Naval signs contract with Terma A/S for Decoy Launching System on...
Oct 10, 2025
INVISIO signs framework agreement worth up to SEK 365 million with Netherlands...
Oct 10, 2025
Rheinmetall to supply Leopard 1-based Skyranger 35 to Ukraine – contract value...